You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

BAYER HLTHCARE Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for BAYER HLTHCARE
International Patents:807
US Patents:37
Tradenames:57
Ingredients:37
NDAs:56

Drugs and US Patents for BAYER HLTHCARE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare LEVLITE ethinyl estradiol; levonorgestrel TABLET;ORAL-21 020860-001 Jul 13, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare NATAZIA dienogest; estradiol valerate TABLET;ORAL 022252-001 May 6, 2010 RX Yes Yes 8,153,616 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare DTIC-DOME dacarbazine INJECTABLE;INJECTION 017575-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes 9,782,414 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare CHILDREN'S ASTEPRO ALLERGY azelastine hydrochloride SPRAY, METERED;NASAL 213872-002 Jun 17, 2021 OTC Yes Yes 8,518,919 ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare MYCELEX clotrimazole SOLUTION;TOPICAL 018181-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes 10,799,505 ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BAYER HLTHCARE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare GADAVIST gadobutrol SOLUTION;INTRAVENOUS 201277-005 Mar 14, 2011 5,980,864 ⤷  Sign Up
Bayer Hlthcare SAFYRAL drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022574-001 Dec 16, 2010 6,441,168 ⤷  Sign Up
Bayer Hlthcare ULTRAVIST 300 iopromide INJECTABLE;INJECTION 020220-002 May 10, 1995 4,364,921 ⤷  Sign Up
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 7,235,576 ⤷  Sign Up
Bayer Hlthcare NATAZIA dienogest; estradiol valerate TABLET;ORAL 022252-001 May 6, 2010 6,133,251 ⤷  Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-003 Aug 19, 2003 7,696,206 ⤷  Sign Up
Bayer Hlthcare SAFYRAL drospirenone; ethinyl estradiol; levomefolate calcium TABLET;ORAL 022574-001 Dec 16, 2010 5,798,338 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAYER HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg ➤ Subscribe 2017-10-10
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 2015-01-08
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-11-13
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 2009-07-10
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 2010-10-22
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 2005-03-22
➤ Subscribe Tablets 40 mg ➤ Subscribe 2016-09-27
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 2009-10-16
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 2005-01-07
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 2007-12-26
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2011-11-21
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-03-05
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2009-09-04
➤ Subscribe Tablets 200 mg ➤ Subscribe 2014-02-28
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-09-28
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 2005-09-12
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 2006-09-29
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2014-02-07

Supplementary Protection Certificates for BAYER HLTHCARE Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3106463 PA2020504 Lithuania ⤷  Sign Up PRODUCT NAME: LAROTREKTINIBAS IR (ARBA) FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, YPAC LAROTREKTINIBO SULFATAS, ISKAITANT LAROTREKTINIBO VANDENILIO SULFATA; REGISTRATION NO/DATE: EU/1/19/1385 20190919
0771217 07C0001 France ⤷  Sign Up PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
1519731 C300740 Netherlands ⤷  Sign Up PRODUCT NAME: AZELASTINE OF EEN; NAT. REGISTRATION NO/DATE: RVG114215 20141125; FIRST REGISTRATION: 2011/07125-REG 20130215
1214076 SZ 49/2008 Austria ⤷  Sign Up PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
1506193 S1400019 Hungary ⤷  Sign Up PRODUCT NAME: RIOCIGUAT; REG. NO/DATE: EU/1/13/97 20140327
1140212 C300666 Netherlands ⤷  Sign Up PRODUCT NAME: RADIUM-223, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/13/873/001 20131113
0780390 PA2004012 Lithuania ⤷  Sign Up PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.